Revna Biosciences (www.RevnaBio.com) has actually sculpted a specific niche for itself in Ghana and West Africa by being the initial center in the area to safeguard twin ISO certifications: ISO 15189:2022 for scientific diagnostics and ISO 20387:2018 for biobanking. This turning point is a testimony to RevnaBio’s steadfast dedication to promoting accuracy medication by driving molecular diagnostics and restorative exploration in the area.
A Promise to Top Quality and Individual Care
The American Organization for Research Laboratory Certification (A2LA) has actually presented the ISO 15189:2022 certification upon Revna Biosciences, recognizing its commitment to providing top-tier scientific screening solutions. The certification procedure required a strenuous on-site examination by A2LA’s assessors, validating the center’s conformity with stringent criteria of accuracy, dependability, and person discretion.
Revna Biosciences’ certification includes a substantial variety of human example examinations, consisting of those entailing pee, swabs, blood, bone marrow, cells examples, and plasma. With a field of expertise in bacteriology, virology, and molecular pathology, the center is committed to supplying people with exact and trustworthy medical diagnoses.
Biobanking Excellence
Revna Biosciences has actually likewise gained certification for its biobanking techniques under ISO 20387:2018. This certification covers the whole biospecimen lifecycle, from collection and purchase to conservation, screening, storage space, and circulation of different cells and blood items. The business’s adherence to global criteria assures the high quality and honesty of biospecimen, consequently adding to innovations in worldwide clinical research study.
Dr. Derrick Edem Akpalu, Chief Executive Officer and Founder of Revna Biosciences, specified, “Our twin ISO certifications mirror our dedication to quality and high quality, from example collection to information evaluation. This not just assures people yet likewise advantages scientists and market companions. These certifications improve our scientific research study solutions, leading the way for worldwide therapies and diagnostics growth. By sticking to these ISO criteria, we guarantee the dependability of our archived biosamples and information, consequently enhancing clinicogenomic understandings and driving the innovation of individualized medication in the area. “
Dr. Yaw Asare-Aboagye, a board participant of the business, included, “We intend to fulfill the greatest global criteria as we are committed to boosting accessibility to excellent medical care and research study centers, specifically in Africa where the need for such solutions is extremely important.”
Global Acknowledgment and Market Alignment
A2LA, the certifying company, is renowned for its Centers for Medicare and Medicaid Provider (CMS) Deemed Standing and International Research Laboratory Certification Teamwork (ILAC) Acknowledgment, a sign of its credibility as a recognizing board in worldwide scientific diagnostics. Additionally, RevnaBio belongs to ISBER, a worldwide discussion forum for biobanking that supporters for top quality criteria and technology in biorepository administration. Revna Biosciences’ success straightens with worldwide acknowledgment and market criteria, placing the business at the lead of clinical technology.
Dispersed by APO Team in support of Revna Biosciences.
Regarding Revna Biosciences:
With a functional base in Accra, Ghana, and offering throughout West Africa, Revna Biosciences (RevnaBio) is a biomedical business devoted to progressing molecular diagnostics and restorative exploration. With a goal to promote accuracy medication for all, RevnaBio is committed to deciphering the organic foundations of conditions influencing Africans, individuals of African descent, and the worldwide populace.
RevnaBio provides a detailed collection of solutions, consisting of sophisticated molecular diagnostics, biobanking, biomarker expedition, scientific research study, main laboratory solutions, condition surveillance, therapy option, and test administration. With calculated partnerships with global biotech leaders such as QIAGEN, Diatech Pharmacogenetics, and Idil Biotech, RevnaBio provides advanced biomedical solutions in the heart of West Africa.
RevnaBio holds all essential regional licenses and licenses, consisting of the Health and wellness Facilities Regulatory Authority (HeFRA) allow for tertiary research laboratories. RevnaBio has the authorization of Ghana’s Food&& Drugs Authority (FDA), is twin ISO certified (ISO 15189:2022; ISO 20387:2018) by the American Organization for Research Laboratory Certification (A2LA) and a participant of the International Culture of Biological and Environmental Repositories (ISBER).
For additional information regarding Revna Biosciences and its innovative operate in accuracy medication, please call +233-59-900-9977 or check out www.RevnaBio.com.
